Aurobindo Pharma Limited (NSE: AUROPHARMA)

Market Cap	892.92B
Revenue (ttm)	297.18B
Net Income (ttm)	35.21B
Shares Out	580.80M
EPS (ttm)	60.10
PE Ratio	25.58
Forward PE	21.96
Dividend	3.00 (0.20%)
Ex-Dividend Date	n/a

Volume	1,043,890
Open	1,533.80
Previous Close	1,533.55
Day's Range	1,516.25 - 1,546.75
52-Week Range	834.65 - 1,584.45
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About Aurobindo Pharma

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1986
• Employees: 26,015
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: AUROPHARMA

Financial Performance

In 2023, AUROPHARMA's revenue was 290.02 billion, an increase of 16.68% compared to the previous year's 248.55 billion. Earnings were 31.73 billion, an increase of 64.62%.